Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Average Rating of “Moderate Buy” by Brokerages

by · The Markets Daily

Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Free Report) has received an average recommendation of “Moderate Buy” from the five research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $3.9375.

LUCD has been the subject of several research reports. Needham & Company LLC reissued a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research note on Thursday, November 13th. Ascendiant Capital Markets lifted their price objective on Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a research report on Wednesday. Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. BTIG Research lifted their price target on shares of Lucid Diagnostics from $2.00 to $2.50 and gave the stock a “buy” rating in a research report on Friday, September 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Lucid Diagnostics in a report on Monday, December 8th.

Read Our Latest Stock Report on Lucid Diagnostics

Lucid Diagnostics Trading Up 1.8%

Shares of LUCD stock opened at $1.16 on Friday. Lucid Diagnostics has a 1 year low of $0.75 and a 1 year high of $1.80. The firm’s 50 day moving average is $1.13 and its 200-day moving average is $1.13. The firm has a market capitalization of $159.71 million, a price-to-earnings ratio of -1.12 and a beta of 1.22.

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The company had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $1.35 million. On average, equities research analysts forecast that Lucid Diagnostics will post -0.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its stake in shares of Lucid Diagnostics by 41.5% during the third quarter. Bank of America Corp DE now owns 40,663 shares of the company’s stock worth $41,000 after purchasing an additional 11,917 shares during the period. Berkshire Asset Management LLC PA bought a new position in Lucid Diagnostics during the first quarter worth about $30,000. Goldman Sachs Group Inc. grew its position in shares of Lucid Diagnostics by 35.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock worth $129,000 after buying an additional 22,727 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Lucid Diagnostics in the 1st quarter valued at about $37,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of Lucid Diagnostics in the 2nd quarter valued at approximately $29,000. 74.01% of the stock is currently owned by institutional investors.

Lucid Diagnostics Company Profile

(Get Free Report)

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.

Read More